Shuoyan Liu

机构：Fujian Medical University, Fujian Provincial Cancer Hospital · ORCID：0000-0003-3749-1256

发表论文 64 篇 · 总被引 927 次 · h-index 16

代表论文

• Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial (2024 · Nature Medicine · 被引 242)
• Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non–Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201) (2023 · Clinical Lung Cancer · 被引 17)
• Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial. (2024 · Journal of Clinical Oncology · 被引 15)
• The advantages of preoperative 3D reconstruction over 2D-CT in thoracoscopic segmentectomy (2024 · Updates in Surgery · 被引 13)
• Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO) (2025 · Nature Communications · 被引 12)
• CACA guidelines for holistic integrative management of esophageal carcinoma (2023 · Holistic Integrative Oncology · 被引 12)